Poorly water soluble drugs present significant challenges in product design and patient compliance including:
- Poor bioavailability leading to high dose and/or multiple dosage units per dose
- Highly variable pharmacokinetics leading to inadequate therapy and/or safety concerns
- Significant food effects on bioavailability leading to dosing restrictions in labeling and consequent patient compliance problems
- Slow or delayed absorption
These challenges may be attributed to inadequate in vivo drug dissolution/solubilization leading to poor and inconsistent bioavailability.
Lip'ral is a patented technology based on lipidic compositions which form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Lip'ral presents insoluble drugs efficiently to the intestinal absorption site, thus bringing the absorption process under formulation control and making the product robust to physiological variables such as dilution, pH and food effects. In some cases, solubilization in the dispersed phase can also improve stability of unstable drug molecules:
- Lip'ral utilizes a wide range of proprietary compositions with bioacceptable excipients
- Lip'ral uses conventional manufacturing processes that are easy to scale-up
Lip'ral enables development of superior oral products with:
- Improved solubilization and high drug loading capacity
- Improved bioavailability leading to reduced dose
- Faster and more consistent absorption leading to reduced variability
- Reduced sensitivity to food effects and improved patient compliance
- Targeted lymphatic delivery
